Nykode Therapeutics ASA announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco. Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic data from the experimental autoimmune encephalomyelitis (EAE) model of Multiple Sclerosis (MS). The updates included demonstrating the disease-modifying effects of two distinct targeting units within its inverse vaccine platform in a therapeutic regimen, highlighting the versatility and effectiveness of antigen-presenting cell (APC)-targeting strategies.

At the conference, Nykode presented data, demonstrating a dose-dependent and disease-modifying effect of its antigen-specific APC-targeting vaccine in a therapeutic regimen, compared to the delivery of antigen alone, emphasizing the platform?s potential for effective antigen-specific treatment for autoimmune disorders. There are approximately 100 different autoimmune diseases affecting about 4% of the world population, representing a significant unmet medical need for novel treatments. Nykode is focusing on developing antigen-specific treatments for autoimmune diseases by using its APC-targeting platform to deliver a tolerogenic response towards disease-associated antigens.